CN Patent

CN119770442A — β-内酰胺化合物和丙磺舒的组合及其用途

Assigned to Italen Treatment International Ltd · Expires 2025-04-08 · 1y expired

What this patent protects

本公开提供了β‑内酰胺化合物和丙磺舒的组合及其用途。本公开涉及双层片剂，所述双层片剂包括第二层，所述第二层包含β‑内酰胺化合物或其药学上可接受的盐；和第一层，所述第一层包含丙磺舒或其药学上可接受的盐。本公开还涉及使用所述双层片剂治疗或预防疾病的方法。

USPTO Abstract

本公开提供了β‑内酰胺化合物和丙磺舒的组合及其用途。本公开涉及双层片剂，所述双层片剂包括第二层，所述第二层包含β‑内酰胺化合物或其药学上可接受的盐；和第一层，所述第一层包含丙磺舒或其药学上可接受的盐。本公开还涉及使用所述双层片剂治疗或预防疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN119770442A
Jurisdiction
CN
Classification
—
Expires
2025-04-08
Drug substance claim
No
Drug product claim
No
Assignee
Italen Treatment International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.